<table id="t4" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4:  Clinically Important Drug Interactions with VIIBRYD
</caption>
<col align="left" width="18.000%"></col>
<col align="left" width="35.667%"></col>
<col align="left" width="46.333%"></col>
<tbody>
<tr>
<td align="center" stylecode="Toprule Botrule Lrule Rrule" valign="middle">
<content stylecode="bold">Concomitant Drug Name or Drug Class</content>
</td>
<td align="center" stylecode="Toprule Botrule Rrule" valign="middle">
<content stylecode="bold">Clinical Rationale</content>
</td>
<td align="center" stylecode="Toprule Botrule Rrule" valign="middle">
<content stylecode="bold">Clinical Recommendation</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="middle">Monoamine Oxidase Inhibitors (MAOIs)
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">The concomitant use of MAOIs and serotonergic drugs including VIIBRYD increases the risk of serotonin syndrome.
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">VIIBRYD is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue <content stylecode="italics">[see Contraindications (<linkhtml href="#s13">4</linkhtml>), Dosage and Administration (<linkhtml href="#s7">2.3</linkhtml>), and Warnings and Precautions (<linkhtml href="#s16">5.2</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="middle">Other Serotonergic Drugs
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">The concomitant use of serotonergic drugs including VIIBRYD and other serotonergic drugs increases the risk of serotonin syndrome.
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">Monitor patients for signs and symptoms of serotonin syndrome, particularly during VIIBRYD initiation.  If serotonin syndrome occurs, consider discontinuation of VIIBRYD and/or concomitant serotonergic drugs <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s16">5.2</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="middle">Antiplatelet Agents and Anticoagulants
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">Serotonin release by platelets plays an important role in hemostasis.  The concurrent use of an antiplatelet agent or anticoagulant with VIIBRYD may potentiate the risk of bleeding.
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">Inform patients of the increased risk of bleeding with the concomitant use of VIIBRYD and antiplatelet agents and anticoagulants.  For patients taking warfarin, carefully monitor the international normalized ratio (INR) when initiating or discontinuing VIIBRYD <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s17">5.3</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="middle">Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin, voriconazole)
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">The concomitant use of VIIBRYD and strong CYP3A4 inhibitors increased the exposure of vilazodone compared to the use of VIIBRYD alone <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s60">12.3</linkhtml>)].</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">The VIIBRYD dose should not exceed 20 mg once daily with the concomitant use of a strong CYP3A4 inhibitor <content stylecode="italics">[see Dosage and Administration (<linkhtml href="#s8">2.4</linkhtml>), Clinical Pharmacology (<linkhtml href="#s60">12.3</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="middle">Strong CYP3A4 Inducers (e.g.,<br/>carbamazepine, phenytoin, rifampin)
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">The concomitant use of VIIBRYD and strong CYP3A4 inducers decreased the exposure of vilazodone compared to the use of VIIBRYD alone <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s60">12.3</linkhtml>)].</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">Based on clinical response, consider increasing the dosage of VIIBRYD, over 1 to 2 weeks in patients taking strong CYP3A4 inducers for greater than 14 days <content stylecode="italics">[see Dosage and Administration (<linkhtml href="#s8">2.4</linkhtml>), Clinical Pharmacology (<linkhtml href="#s60">12.3</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="middle">Digoxin
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">Digoxin is a narrow therapeutic index drug. Concomitant use of VIIBRYD increased digoxin concentrations <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s60">12.3</linkhtml>)]</content>.
</td>
<td align="left" stylecode="Botrule Rrule" valign="middle">Measure serum digoxin concentrations before initiating concomitant use of VIIBRYD. Continue monitoring and reduce digoxin dose as necessary.<br/>
</td>
</tr>
</tbody>
</table>